COPL — what changed in the latest 10-Q
A section-by-section comparison of COPL's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-17 vs the prior 10-Q · 2026-05-20
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +9 | −6 | ~8 | 19 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 4 |
| Risk factors | Some risk factors updated | +3 | −1 | 0 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Legal proceedings, Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-17
On June 10, 2026, the Company entered into a Business Combination Agreement with Ignite Proteomics Holdings, Inc., Ignite Proteomics, LLC and affiliated merger entities pursuant to which the parties agreed to consummate a business combination transaction, subject to the satisfaction of customary clo…
We have neither engaged in any operations nor generated any revenues to date. Our only activities since inception have been organizational activities, those necessary to prepare for the IPO and those related to identifying and evaluating an initial business combination target and, following executio…
For the three and six months ended June 30, 2026, we had a net income of $1,485,641 and $2,774,553 respectively which consisted primarily of dividends earned on marketable securities held in the Trust Account, partially offset by general and administrative expenses. For the three and six months ende…
On May 2, 2025, we consummated our IPO of 15,000,000 units (the “Units”), at $10.00 per Unit, generating gross proceeds of $150,000,000. Simultaneously with the closing of our IPO, we consummated the sale of 499,643 Private Placement Units at a price of $10.00 per Private Placement Unit for the firs…
On June 10, 2026, the Company entered into a definitive Business Combination Agreement relating to a proposed business combination with Ignite Proteomics, LLC. Under the terms of the Business Combination Agreement, completion of the proposed transaction is subject to minimum financing requirements. …
Text removed vs the prior filing · source: 10-Q · 2026-05-20
We have neither engaged in any operations nor generated any revenues to date. Our only activities since inception have been organizational activities, those necessary to prepare for the IPO and those related to our search for an initial business combination. Following the IPO, we will not generate a…
For the three months ended March 31, 2026, we had a net income of $1,288,912, which consisted primarily of dividends earned on marketable securities held in the Trust Account, partially offset by general and administrative expenses. For the three months ended March 31, 2025, we had a net loss of $74…
On May 2, 2025, we consummated our IPO of 15,000,000 units (the “Units”), at $10.00 per Unit, generating gross proceeds of $150,000,000. Simultaneously with the closing of our IPO, we consummated the sale of 499,643 Private Placement Units at a price of $10.00 per Private Placement Unit for the firs…
To address this uncertainty, the Company is currently evaluating several options to improve its liquidity position. These include raising additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company’s officers, director…
If the Company is unable to secure additional funding, it may be required to take measures to conserve liquidity, which could include, but are not limited to, curtailing operations, suspending the pursuit of a potential business combination, and reducing overhead expenses.
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-17
In addition to the other information set forth in this report, you should carefully consider the factors discussed in “Risk Factors” contained in our (i) Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission (the “SEC”) on March …
On June 10, 2026, we entered into a Business Combination Agreement with Ignite Proteomics, LLC (“Ignite”) and certain other parties, as more fully described in our Current Report on Form 8-K filed with the SEC on June 11, 2026. The proposed business combination is subject to numerous risks and uncer…
A comprehensive discussion of risks related to the proposed business combination and the business of Ignite will be included in the registration statement on Form S-4 to be filed with the SEC in connection with the proposed transaction.
Text removed vs the prior filing · source: 10-Q · 2026-05-20
In addition to the other information set forth in this report, you should carefully consider the factors discussed in “Risk Factors” of our Prospectus dated April 30, 2025, which could materially affect our business, financial condition or future results. There have been no material changes during o…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice